[go: up one dir, main page]

CN107898829A - Advanced glycation end products decomposition agent - Google Patents

Advanced glycation end products decomposition agent Download PDF

Info

Publication number
CN107898829A
CN107898829A CN201710879511.9A CN201710879511A CN107898829A CN 107898829 A CN107898829 A CN 107898829A CN 201710879511 A CN201710879511 A CN 201710879511A CN 107898829 A CN107898829 A CN 107898829A
Authority
CN
China
Prior art keywords
under
bhfs
age
bsa
pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710879511.9A
Other languages
Chinese (zh)
Inventor
朴春红
霍越
李想
赵梓瀛
唐玉芳
刘俊梅
王玉华
于寒松
代伟长
周亚楠
王尚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jilin Agricultural University
Original Assignee
Jilin Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jilin Agricultural University filed Critical Jilin Agricultural University
Priority to CN201710879511.9A priority Critical patent/CN107898829A/en
Publication of CN107898829A publication Critical patent/CN107898829A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/51Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

本发明公开了一种荞麦壳黄酮提取物在制备糖基化终末产物裂解剂方面的应用,所述的荞麦壳黄酮提取物是将荞麦壳粉碎、过筛,加入水,超高压处理;过滤,真空浓缩,冷冻干燥,即获得荞麦壳黄酮提取物;用磷酸盐缓冲液配置溶液,作为糖基化终末产物裂解剂;构建了体外非酶糖基化反应体系,结果表明,荞麦壳黄酮提取物可以裂解糖基化终末产物。The invention discloses an application of buckwheat husk flavone extract in the preparation of a glycosylation end product cracking agent. The buckwheat husk flavone extract is crushed, sieved, added to water, and subjected to ultra-high pressure treatment; filtered , concentrated in vacuum, and freeze-dried to obtain buckwheat husk flavonoid extract; use phosphate buffer to configure the solution as a splitting agent for glycation end products; construct an in vitro non-enzymatic glycosylation reaction system, and the results show that buckwheat husk flavonoids The extract cleaves glycation end products.

Description

糖基化终末产物裂解剂Glycation end product splitting agent

技术领域technical field

本发明属于保健食品和药品领域,具体涉及糖基化终末产物裂解剂。The invention belongs to the field of health food and medicine, and in particular relates to a splitting agent for end product of glycation.

背景技术Background technique

糖基化终末产物(Advanced Glycation End Products,AGEs)是指还原糖与氨基酸或脂类等大分子经非酶糖基化反应得到的终末期产物,人体内AGEs的过度积累可以导致糖尿病及其并发症、阿尔茨海默病和一系列心血管疾病的产生与发展。大量研究证实,引发糖尿病并发症的根本物质是AGEs。AGEs的来源分为内源性和外源性两种,由生物机体内的糖类与蛋白质发生糖化反应而产生的,称作内源性AGEs,体内AGEs的形成可以升高体内葡萄糖利用率,加剧胰岛素抵抗和氧化应激反应,通过多种路径引起细胞内外血管内皮细胞的变化,干扰重要器官的组织结构的正常机能;外源性主要来自富含碳水化合物和含脂肪多的食物,另有报导吸烟可产生AGEs,从食品、饮料或香烟烟雾中摄入的外源性AGEs能够显著升高其在血液中的浓度,从而引发胰岛素抵抗并加速组织特异性损伤。因此具有切断人体组织蛋白间的AGE交联,分解应经形成的AGEs作用的AGEs裂解剂成为了治疗多种疾病的新靶标。Glycation end products (Advanced Glycation End Products, AGEs) refer to the end products obtained by non-enzymatic glycosylation of macromolecules such as reducing sugars and amino acids or lipids. Excessive accumulation of AGEs in the human body can lead to diabetes and other diseases. Complications, Alzheimer's disease and the development and progression of a range of cardiovascular diseases. A large number of studies have confirmed that AGEs are the fundamental substances that cause diabetic complications. The sources of AGEs are divided into two types: endogenous and exogenous. They are produced by the saccharification reaction of carbohydrates and proteins in living organisms. They are called endogenous AGEs. The formation of AGEs in the body can increase the utilization rate of glucose in the body. Exacerbate insulin resistance and oxidative stress response, cause changes in intracellular and extracellular vascular endothelial cells through various channels, and interfere with the normal function of the tissue structure of important organs; exogenous sources mainly come from foods rich in carbohydrates and fats, and other It is reported that smoking can produce AGEs, and exogenous AGEs ingested from food, beverage or cigarette smoke can significantly increase its concentration in blood, thereby triggering insulin resistance and accelerating tissue-specific damage. Therefore, the AGEs cracking agent which has the function of cutting off the AGE cross-linking between human tissue proteins and decomposing the AGEs that should be formed has become a new target for the treatment of various diseases.

1996年,Vasan等人首先提出了AGEs裂解剂这一概念,其被定义为可以分解已经形成AGEs的物质,能切断AGEs组织蛋白间已经形成的AGE交联。第一个合成的AGEs裂解剂——N-苯甲酰基噻唑溴化物被证明可以逆转与糖尿病胶原间的AGE交联,释放与糖尿病大鼠的红细胞表面交联的免疫球蛋白G(IgG),并且逆转在体外由AGEs修饰形成的淀粉样蛋白纤维的聚集。但随后的研究中,由于该化合物在水溶液中的不稳定性,N-苯亚甲基噻唑鎓溴化物在临床应用阶段宣告失败。随后,Vasan又于2003年提出结构更加稳定、活性更高的化合物ALT-711(4, 5-二甲基 -3-苯乙酰基噻唑嗡氯化物),现已经完成 II期临床研究,与之相似的一系列AGEs裂解剂陆续也被开发,如C24、C36及C36D2等。该裂解剂与AGEs结合后,能够反应生成易自发裂解的结构,切断胶原及其他生物大分子形成交联结构的桥梁,使蛋白质重新游离出来,并随之恢复自身功能。ALT-711还可以逆转糖尿病和高血压动物模型中由AGE交联引起的心血管硬化。AGEs裂解剂的研究特性在于,首先在一定的反应体系下形成稳定的AGEs,然后再加入裂解剂进行裂解,裂解剂全程不参与此过程。为了保证裂解剂的作用环境稳定不受干扰,其对于非酶糖基化反应体系的要求更高。目前在现有的AGEs裂解剂研究报道中,对反应体系影响因素的研究主要集中在反应物、温度与制备AGEs的培养时间和非酶糖基化体系的抑菌方式几个方面。In 1996, Vasan et al. first proposed the concept of AGEs cracking agent, which is defined as the substance that can decompose AGEs and can cut off the AGE crosslinks that have formed between AGEs tissue proteins. The first synthetic AGEs cleavage agent, N-benzoylthiazole bromide, was shown to reverse AGE crosslinks with diabetic collagen, releasing immunoglobulin G (IgG) crosslinked to the surface of erythrocytes in diabetic rats, And reverse the aggregation of amyloid fibrils formed by AGEs modification in vitro. However, in subsequent studies, due to the instability of the compound in aqueous solution, N-benzylidene thiazolium bromide failed in clinical application. Subsequently, Vasan proposed a compound ALT-711 (4,5-dimethyl-3-phenylacetylthiazole chloride) with a more stable structure and higher activity in 2003, which has completed phase II clinical research. A series of similar cracking agents for AGEs have also been developed, such as C24, C36 and C36D2. After the cleavage agent is combined with AGEs, it can react to form a structure that is easy to cleavage spontaneously, cut off the bridge of cross-linked structure formed by collagen and other biomacromolecules, make the protein free again, and then restore its own function. ALT-711 also reversed cardiovascular stiffness induced by AGE crosslinking in animal models of diabetes and hypertension. The research characteristic of AGEs cracking agent is that stable AGEs are first formed under a certain reaction system, and then cracking agent is added to crack, and the cracking agent does not participate in the whole process. In order to ensure that the working environment of the cleavage agent is stable and uninterrupted, it has higher requirements for the non-enzymatic glycosylation reaction system. At present, in the existing research reports on AGEs splitting agents, the research on the influencing factors of the reaction system mainly focuses on the reactants, temperature, incubation time for preparing AGEs, and the antibacterial mode of the non-enzymatic glycosylation system.

在我国北方经典的农作物——荞麦中,含有丰富的黄酮。荞麦为蓼科(Polygonacca)荞麦属(Fagopyrum Mill),广泛分布于亚洲和欧洲。大量研究证据表明,荞麦中含有大量的芦丁、槲皮素等黄酮类化合物,具有多种药理作用,如预防和治疗糖尿病、降血脂等。荞麦壳作为荞麦加工的副产物,在高值化利用方面技术严重缺乏,造成了资源的极大浪费。荞麦壳中含有大量的黄酮类物质,其对AGEs的形成的抑制作用在先前的研究中得到充分的证实,但对AGEs的裂解作用未见报道。Buckwheat, a classic crop in northern my country, is rich in flavonoids. Buckwheat belongs to the genus Fagopyrum Mill of the Polygonacca family and is widely distributed in Asia and Europe. A lot of research evidence shows that buckwheat contains a lot of flavonoids such as rutin and quercetin, which have various pharmacological effects, such as preventing and treating diabetes and lowering blood fat. As a by-product of buckwheat processing, buckwheat husk is seriously lacking in high-value utilization technology, resulting in a great waste of resources. Buckwheat husk contains a large amount of flavonoids, and its inhibitory effect on the formation of AGEs has been fully confirmed in previous studies, but the cracking effect on AGEs has not been reported.

发明内容Contents of the invention

本发明的目的是提供了一种天然糖基化终末产物裂解剂。The object of the present invention is to provide a natural glycosylation end product splitting agent.

荞麦壳黄酮提取物在制备糖基化终末产物裂解剂方面的应用;Application of buckwheat husk flavonoid extract in the preparation of glycosylation end product splitting agent;

所述的荞麦壳黄酮提取物,是由下述方法制备的:The buckwheat husk flavone extract is prepared by the following method:

1)将荞麦壳粉碎、过60-80目筛,按料液质量比1:5-20加入水,高压加热;1) Crush the buckwheat husk, pass through a 60-80 mesh sieve, add water according to the mass ratio of material to liquid 1:5-20, and heat under high pressure;

2)过滤,在55-65℃下真空浓缩,冷冻干燥20-30h,即获得荞麦壳黄酮提取物。2) Filtration, vacuum concentration at 55-65°C, and freeze-drying for 20-30 hours to obtain buckwheat husk flavone extract.

步骤1)中所述的高压加热为121℃下加热15-25min。The high-pressure heating described in step 1) is heating at 121° C. for 15-25 minutes.

步骤1)中所述的高压加热为采用超高压处理装置,压力100-400MPa、保持压力1-5min,高压稳定处理。The high-pressure heating described in step 1) adopts an ultra-high pressure treatment device, the pressure is 100-400MPa, the pressure is maintained for 1-5min, and the high-pressure treatment is stable.

步骤1)中所述的压力为300MPa,保持压力时间2min。The pressure described in step 1) is 300MPa, and the pressure is maintained for 2 minutes.

本发明提供了荞麦壳黄酮提取物在制备糖基化终末产物裂解剂方面的应用。所述的荞麦壳黄酮提取物是将荞麦壳粉碎、过筛,加入水,超高压处理;过滤,真空浓缩,冷冻干燥,即获得荞麦壳黄酮提取物;用磷酸盐缓冲液配置溶液,作为糖基化终末产物裂解剂;构建了体外非酶糖基化反应体系,结果表明,荞麦壳黄酮提取物可以裂解糖基化终末产物。The invention provides the application of buckwheat husk flavonoid extract in the preparation of glycosylation end product splitting agent. The buckwheat husk flavonoid extract is obtained by crushing buckwheat husk, sieving, adding water, and ultra-high pressure treatment; filtering, vacuum concentration, and freeze-drying to obtain the buckwheat husk flavonoid extract; using phosphate buffer solution to prepare the solution as sugar glycosylation end-product cleavage agent; the in vitro non-enzymatic glycosylation reaction system was constructed, and the results showed that buckwheat husk flavonoid extract could cleavage the glycosylation end-product.

附图说明Description of drawings

图1 非酶糖基化体系体系荧光值,A为AGE-G-BSA体系,B为AGE-F-BSA体系;Figure 1 Fluorescence value of non-enzymatic glycosylation system, A is AGE-G-BSA system, B is AGE-F-BSA system;

图2 BHFs裂解AGE-G-BSA体系荧光值;A为NaN3条件下浓度为0.05mg/mL时;B为NaN3条件下浓度为0.20mg/mL时;C为MSF条件下浓度为0.05mg/mL时;D为MSF条件下浓度为0.05mg/mL时;Fig.2 The fluorescence value of AGE-G-BSA system cracked by BHFs; A is the concentration of 0.05mg/mL under the condition of NaN3 ; B is the concentration of 0.20mg/mL under the condition of NaN3 ; C is the concentration of 0.05mg under the condition of MSF /mL; D is when the concentration is 0.05mg/mL under MSF conditions;

图3 BHFs裂解AGE-F-BSA体系荧光值;A为NaN3条件下浓度为0.05mg/mL时;B为NaN3条件下浓度为0.20mg/mL时;C为MSF条件下浓度为0.05mg/mL时;D为MSF条件下浓度为0.05mg/mL时;Fig.3 The fluorescence value of AGE-F-BSA system cracked by BHFs; A is the concentration of 0.05mg/mL under the condition of NaN3 ; B is the concentration of 0.20mg/mL under the condition of NaN3 ; C is the concentration of 0.05mg under the condition of MSF /mL; D is when the concentration is 0.05mg/mL under MSF conditions;

图4非酶糖基化体系体系蛋白平均分子量;A为AGE-G-BSA体系NaN3条件;B为AGE-G-BSA体系MSF条件;C为AGE-G-BSA体系NaN3条件;D为AGE-G-BSA体系MSF条件;Figure 4 The average molecular weight of protein in the non-enzymatic glycosylation system; A is the NaN 3 condition of the AGE-G-BSA system; B is the MSF condition of the AGE-G-BSA system; C is the NaN 3 condition of the AGE-G-BSA system; D is AGE-G-BSA system MSF conditions;

图5 BHFs裂解前后AGE-G-BSA体系葡萄糖含量;Figure 5 Glucose content in AGE-G-BSA system before and after BHFs cleavage;

图6 BHFs裂解前后AGE-F-BSA体系AGEs果糖含量;Figure 6 AGEs fructose content in AGE-F-BSA system before and after BHFs cracking;

图7 BHFs裂解前后AGE-G-BSA体系AGEs游离氨基含量;Fig.7 Content of free amino groups in AGEs in AGE-G-BSA system before and after BHFs cracking;

图8 BHFs裂解前后AGE-F-BSA体系AGEs游离氨基含量。Fig. 8 Content of free amino groups of AGEs in AGE-F-BSA system before and after BHFs cleavage.

具体实施方式Detailed ways

实施例1糖基化终末产物裂解剂的制备The preparation of embodiment 1 glycosylation end product splitting agent

将干燥后的荞麦壳用高速粉碎机粉碎、过60目筛,放入干净的烧杯中,按质量比1:10加入蒸馏水,在121℃条件下,高压加热20min;过滤,滤渣重复提取2次;将滤液合并,在60℃条件下真空浓缩至膏状,冷冻干燥24h成粉末,即获得荞麦壳黄酮提取物(Buckwheat HullFlavonoid extracts, BHFs);将荞麦壳黄酮提取物用磷酸盐缓冲液(PBS,200mM,pH=7.4)配置成0.05mg/mL的溶液,作为糖基化终末产物裂解剂(BHFs)。Grind the dried buckwheat husks with a high-speed grinder, pass through a 60-mesh sieve, put them into a clean beaker, add distilled water at a mass ratio of 1:10, heat at 121°C for 20 minutes under high pressure; filter, and extract the filter residue twice ; The filtrates were combined, concentrated in vacuo at 60°C to a paste, and freeze-dried for 24 hours to form a powder to obtain Buckwheat Hull Flavonoid extracts (BHFs); the Buckwheat Hull Flavonoid extracts were washed with phosphate buffered saline (PBS , 200mM, pH=7.4) was configured into a 0.05mg/mL solution, as a splitting agent for glycation end products (BHFs).

实施例2糖基化终末产物裂解剂的制备The preparation of embodiment 2 glycosylation end product cracking agent

将干燥后的荞麦壳用高速粉碎机粉碎、过60目筛,放入干净的烧杯中,按质量比1:10加入蒸馏水,在121℃条件下,高压加热20min;过滤,滤渣重复提取2次;将滤液合并,在60℃条件下真空浓缩至膏状,冷冻干燥24h成粉末,即获得荞麦壳黄酮提取物(Buckwheat HullFlavonoid extracts, BHFs);将荞麦壳黄酮提取物用磷酸盐缓冲液(PBS,200mM,pH=7.4)配置成0.2mg/mL的溶液,作为糖基化终末产物裂解剂(BHFs)。Grind the dried buckwheat husks with a high-speed grinder, pass through a 60-mesh sieve, put them into a clean beaker, add distilled water at a mass ratio of 1:10, heat at 121°C for 20 minutes under high pressure; filter, and extract the filter residue twice ; The filtrates were combined, concentrated in vacuo at 60°C to a paste, and freeze-dried for 24 hours to form a powder to obtain Buckwheat Hull Flavonoid extracts (BHFs); the Buckwheat Hull Flavonoid extracts were washed with phosphate buffered saline (PBS , 200mM, pH=7.4) was configured into a 0.2mg/mL solution as a splitting agent for glycation end products (BHFs).

实施例3糖基化终末产物裂解剂的制备Example 3 Preparation of glycosylation end product splitting agent

将荞麦壳干燥,用高速粉碎机粉碎、过80目筛,按质量比1:20加入水,采用超高压处理装置进行压力300MPa、保压2min的高压稳定处理;过滤,在60℃条件下真空浓缩至膏状,冷冻干燥24h成粉末,即获得荞麦壳黄酮提取物(Buckwheat Hull Flavonoid extracts,BHFs);将荞麦壳黄酮提取物用磷酸盐缓冲液(PBS,200mM,pH=7.4)配置成0.2mg/mL的溶液,作为糖基化终末产物裂解剂(BHFs)。Dry buckwheat husks, pulverize them with a high-speed grinder, pass through an 80-mesh sieve, add water at a mass ratio of 1:20, and use an ultra-high pressure treatment device to perform high-pressure stabilization treatment at a pressure of 300 MPa and hold for 2 minutes; filter and vacuum at 60°C Concentrate to a paste, freeze-dry for 24 hours to form a powder, and then obtain Buckwheat Hull Flavonoid extracts (BHFs); the Buckwheat Hull Flavonoid extracts are prepared with phosphate buffer (PBS, 200mM, pH=7.4) to 0.2 mg/mL solution as a splitting agent for glycation end products (BHFs).

实施例4 体外非酶糖基化体系的建立Example 4 Establishment of in vitro non-enzymatic glycosylation system

1. 叠氮化钠条件下体外非酶糖基化体系的建立1. Establishment of in vitro non-enzymatic glycosylation system under the condition of sodium azide

在超净条件下分别用混有0.02%叠氮化钠(NaN3)的磷酸盐缓冲液(PBS,200mM,pH=7.4)配置出10.00mg/mL的牛血清白蛋白(Bovine Serum Albumin, BSA)溶液和500mM的葡萄糖(Glycation,G)或果糖(Fructose,F),向5mL糖溶液中加入10mL BSA溶液,分别制备糖基化-葡萄糖-牛血清白蛋白体系(AGE-G-BSA)和糖基化-果糖-牛血清白蛋白体系(AGE-F-BSA),混合均匀后在37℃条件下避光反应6个月,这期间分别在第1、2、3、4、5、6个月取出部分样品,暂存于-80℃。Under ultra-clean conditions, 10.00mg/ mL bovine serum albumin (Bovine Serum Albumin, BSA ) solution and 500mM glucose (Glycation, G) or fructose (Fructose, F), add 10mL BSA solution to 5mL sugar solution to prepare glycosylation-glucose-bovine serum albumin system (AGE-G-BSA) and Glycosylation-fructose-bovine serum albumin system (AGE-F-BSA), after mixing evenly, react in the dark at 37°C for 6 months, during this period, respectively, in the 1st, 2nd, 3rd, 4th, 5th, 6th Some samples were taken out every month and temporarily stored at -80°C.

2. 微孔抽滤条件下体外非酶糖基化体系的建立2. Establishment of non-enzymatic glycosylation system in vitro under the condition of microporous suction filtration

在上述条件的基础上采用微孔滤膜抽滤的方式(Micro-aperture suction filter,MSF )对反应试剂灭菌。具体为,采用不含NaN3的磷酸盐缓冲液(PBS,200mM,pH=7.4)配置反应试剂,随后将反应试剂依次通过孔径为0.45μm和0.22μm的微孔滤膜,混合均匀后在37℃条件下避光反应6个月,这期间分别在第1、2、3、4、5、6个月取出部分样品,暂存于-80℃,则为待裂解的AGEs。On the basis of the above conditions, the reaction reagents were sterilized by means of microporous membrane suction filtration (Micro-aperture suction filter, MSF). Specifically, the reaction reagents were prepared using NaN 3 -free phosphate buffer solution (PBS, 200 mM, pH=7.4), and then the reaction reagents were sequentially passed through microporous membranes with pore diameters of 0.45 μm and 0.22 μm. Under the condition of ℃, the reaction was protected from light for 6 months. During this period, some samples were taken out at the 1st, 2nd, 3rd, 4th, 5th, and 6th months, and temporarily stored at -80℃, which were AGEs to be cleaved.

3. 体外非酶糖基化体系的裂解3. Cleavage of In Vitro Non-enzymatic Glycosylation System

在超净条件下向制备好的AGE-G-BSA体系和AGE-F-BSA体系中分别加入浓度为0.05mg/mL和0.20mg/mL的糖基化终产物裂解剂,未加入裂解剂的体系作为空白组,相同浓度的氨基胍(Aminoguanidine,AG)作为阳性对照,混合均匀后在37℃条件下避光裂解6天,样品保存于-80℃。Add 0.05 mg/mL and 0.20 mg/mL lysing agent for end-glycosylation products to the prepared AGE-G-BSA system and AGE-F-BSA system under ultra-clean conditions, respectively. The system was used as a blank group, and the same concentration of aminoguanidine (Aminoguanidine, AG) was used as a positive control. After mixing evenly, it was lysed at 37°C in the dark for 6 days, and the samples were stored at -80°C.

实施例5 非酶糖基化反应体系动力学实验Example 5 Kinetic experiment of non-enzymatic glycosylation reaction system

AGEs是一类复杂的混合物,其中含有大量的具有荧光交联性的物质,如戊糖素,因此荧光值成为AGEs的量化重要指标,研究学者们广泛采用的方法。通常以样品在激发波长355nm,发射波长460nm左右的荧光强度来表现体系中非酶糖基化反应程度和AGEs生成量。利用荧光酶标仪在增益50,激发波长355nm,发射波长460nm处测定裂解前后体系的荧光值,并利用下列公式计算出裂解率:AGEs are a kind of complex mixture, which contains a large number of fluorescent cross-linking substances, such as pentosidine, so the fluorescence value has become an important quantitative indicator of AGEs, and is widely used by researchers. Usually, the fluorescence intensity of the sample at an excitation wavelength of 355nm and an emission wavelength of about 460nm is used to express the degree of non-enzymatic glycosylation reaction and the amount of AGEs generated in the system. Use a fluorescent microplate reader at a gain of 50, an excitation wavelength of 355nm, and an emission wavelength of 460nm to measure the fluorescence value of the system before and after lysis, and use the following formula to calculate the lysis rate:

(公式1) (Formula 1)

如图1A所示,在AGE-G-BSA体系中,在反应时间为1-4个月的时间内,体系荧光值随反应时间的增长而显著增大(p<0.05),当反应进行到第5个月时,荧光值与第4个月相比显著减少(p<0.05),反应进行到第6个月时又升高,为135450.50±50.00,显著高于第4、第5个月(p <0.05达到其在1个月时的3倍以上。AGE-F-BSA体系中的荧光值如图1B所示。在NaN3条件下,反应在3个月以内荧光值显著增长(p<0.05),然而当反应进行到第4个月时,体系荧光值显著减少到其在第三个月的56.08%(p<0.05),接下来体系荧光值在的第4.5.6个月的反应时间内显著增长(p<0.05);而在MSF条件下,体系荧光值基本呈逐步增长趋势,最大达到205647.50±731.00。AGE-F-BSA体系的荧光值显著高于AGE-G-BSA体系,这可能与果糖与BSA的反应相对剧烈,体系中AGEs含量较多有关。As shown in Figure 1A, in the AGE-G-BSA system, within the reaction time of 1-4 months, the fluorescence value of the system increased significantly with the increase of the reaction time ( p<0.05 ), when the reaction At the 5th month, the fluorescence value decreased significantly compared with the 4th month ( p<0.05 ), and the reaction increased again at the 6th month, which was 135450.50±50.00, which was significantly higher than the 4th and 5th month ( p <0.05 ) , reaching more than 3 times that at 1 month. The fluorescence values in the AGE-F-BSA system are shown in Figure 1B. Under the NaN 3 condition, the fluorescence value of the reaction increased significantly within 3 months ( p<0.05 ), but when the reaction progressed to the 4th month, the fluorescence value of the system decreased significantly to 56.08% of that in the third month ( p <0.05 ), then the fluorescence value of the system increased significantly in the reaction time of 4.5.6 months ( p<0.05 ); while under MSF conditions, the fluorescence value of the system basically showed a gradual increase trend, reaching a maximum of 205647.50±731.00. The fluorescence value of AGE-F-BSA system was significantly higher than that of AGE-G-BSA system, which may be related to the relatively violent reaction between fructose and BSA and the high content of AGEs in the system.

两种不同灭菌方式比较,结果表明MSF组荧光值基本高于NaN3组,两种条件下的荧光值在反应早期时(第1、2个月)差异并不明显,当反应进行到第3个月后开始表现出显著性差异(p<0.05),尤其在AGE-F-BSA体系中当反应进行到第4个月时,MSF组荧光值约为NaN3组的2.11倍。在接下来的实验中为了简化实验步骤,选择具有代表性的反应时间为1、3、6个月的体系对BHFs的裂解效果进行研究。Comparing the two different sterilization methods, the results show that the fluorescence value of MSF group is basically higher than that of NaN 3 group, and the difference of fluorescence value under the two conditions is not obvious in the early stage of reaction (1st and 2nd month). After 3 months, there was a significant difference ( p<0.05 ), especially in the AGE-F-BSA system, when the reaction reached the 4th month, the fluorescence value of the MSF group was about 2.11 times that of the NaN 3 group. In the following experiments, in order to simplify the experimental steps, representative systems with reaction times of 1, 3, and 6 months were selected to study the cracking effect of BHFs.

实施例6 糖基化终末产物裂解剂BHFs的特性实验Example 6 Characteristic experiment of glycation end product splitting agent BHFs

1. BHFs对AGEs荧光值的作用1. The effect of BHFs on the fluorescence value of AGEs

(1) BHFs对AGE-G-BSA体系荧光值的作用(1) The effect of BHFs on the fluorescence value of AGE-G-BSA system

选择AG作为阳性对照。BHFs及AG对AGE-G-BSA体系荧光值的作用如图2所示。由图可知,在NaN3条件下,BHFs的抑制率呈现显著的浓度-剂量依赖关系(p<0.05),其裂解作用显著强于AG(p<0.05)。在浓度为0.05mg/mL的条件下,BHFs对反应时间为3个月的体系裂解作用最强,而在浓度为0.20mg/mL的条件下,BHFs对反应时间为3、6个月的体系裂解作用相当,最高达到30.88±0.04%(体系反应时间为6个月),为相同条件下AG的裂解率(11.04±0.46%)的2.80倍。AG was chosen as a positive control. The effect of BHFs and AG on the fluorescence value of AGE-G-BSA system is shown in Figure 2. It can be seen from the figure that under the condition of NaN 3 , the inhibition rate of BHFs showed a significant concentration-dose dependent relationship ( p<0.05 ), and its cleavage effect was significantly stronger than that of AG ( p<0.05 ). At a concentration of 0.05 mg/mL, BHFs had the strongest cracking effect on the system with a reaction time of 3 months. The cleavage effect is equivalent, the highest reaches 30.88±0.04% (the system reaction time is 6 months), which is 2.80 times of the cleavage rate of AG (11.04±0.46%) under the same conditions.

在MSF条件下也可以得到相似的结论。在浓度为0.20mg/mL的条件下,BHFs对反应时间6个月的体系裂解作用最高,最高达到27.85±0.58%。特别的,在MSF条件下,0.05mg/mL的BHF和AG对反应时间为一个月的体系抑制效果较弱,尤其是BHFs的裂解效果仅为NaN3条件下的9.74%。在浓度为0.20mg/mL的条件下,BHFs和AG的裂解作用均弱于NaN3组。Similar conclusions can also be obtained under MSF conditions. Under the condition of concentration of 0.20mg/mL, the cracking effect of BHFs on the system with a reaction time of 6 months was the highest, up to 27.85±0.58%. In particular, under MSF conditions, 0.05 mg/mL of BHF and AG had a weak inhibitory effect on the system with a reaction time of one month, especially the cracking effect of BHFs was only 9.74% of that under NaN 3 conditions. At the concentration of 0.20mg/mL, the cracking effect of BHFs and AG was weaker than that of NaN 3 group.

(2) BHFs对AGE-F-BSA体系荧光值的作用(2) The effect of BHFs on the fluorescence value of AGE-F-BSA system

如图3所示,BHFs对AGE-F-BSA体系荧光值的作用与AGE-G-BSA体系有所不同,BHFs的抑制率呈现显著的浓度-剂量依赖关系(p<0.05)。由图3A、图3B 可知,在NaN3条件下,在浓度为0.05mg/mL的条件下,BHFs和AG对体系荧光值的作用相对较弱,而在浓度为0.20mg/mL的条件下,BHFs的裂解效果显著强于AG(p<0.05),对反应时间为1个月的体系裂解作用最强,为29.69±0.67%。As shown in Figure 3, the effect of BHFs on the fluorescence value of AGE-F-BSA system was different from that of AGE-G-BSA system, and the inhibition rate of BHFs showed a significant concentration-dose-dependent relationship ( p<0.05 ). It can be seen from Fig. 3A and Fig. 3B that under the condition of NaN 3 , when the concentration is 0.05 mg/mL, the effect of BHFs and AG on the fluorescence value of the system is relatively weak, while under the condition of 0.20 mg/mL, the The lysis effect of BHFs was significantly stronger than that of AG ( p<0.05 ), and the lysis effect on the system with a reaction time of 1 month was the strongest, which was 29.69±0.67%.

在MSF条件下也可以得到相似的结论,在浓度为0.05mg/mL的条件下,BHFs对反应时间6个月的体系裂解作用显著高于AG(p<0.05),当浓度为0.20mg/mL时,AG对体系的裂解作用随体系反应时间的增长而显著减弱(p<0.05),该结果与在NaN3条件下的结果一致,BHFs裂解效果显著强于AG(p<0.05),与在NaN3条件下的结果不同的是BHFs对反应时间为6个月的体系裂解作用最强,为28.92±0.57%,低于其在NaN3条件下的最高裂解率。Similar conclusions can also be obtained under MSF conditions. At the concentration of 0.05mg/mL, the cracking effect of BHFs on the reaction time of 6 months was significantly higher than that of AG ( p<0.05 ), and when the concentration was 0.20mg/mL , the cracking effect of AG on the system was significantly weakened with the increase of the reaction time of the system ( p<0.05 ), which was consistent with the results under the NaN 3 condition, and the cracking effect of BHFs was significantly stronger than that of AG ( p<0.05 ), which was consistent with The difference in the results under the NaN 3 condition is that the cracking effect of BHFs on the system with a reaction time of 6 months is the strongest, which is 28.92±0.57%, which is lower than its highest cracking rate under the NaN 3 condition.

2. BHFs对AGEs蛋白分子量的作用2. The effect of BHFs on the molecular weight of AGEs protein

通过基质辅助激光解吸电离-飞行时间质谱(MALDI-TOF/TOF)在正离子模式下选择线性方法对BHFs裂解前后体系蛋白分子量进行分析,试验产生的原始数据及图谱由4000SeriesExplorer V3.5软件导出。The protein molecular weight of the system before and after BHFs cleavage was analyzed by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF/TOF) in positive ion mode, and the original data and spectra were exported by 4000SeriesExplorer V3.5 software.

(1)非酶糖基化体系体系蛋白分子量(1) Non-enzymatic glycosylation system protein molecular weight

MALDI-TOF/TOF通过单个体系点光谱中的主峰对样品分子量进行测定,分子量的增加与主峰的扩展显著相关,表明在非酶糖基化反应过程中产生一系列的蛋白修饰,由图4可知,试验中所使用的BSA分子量为66993.06Da,在空白组中,随着反应时间的增长,体系分子量逐步增加,AGE-G-BSA体系和AGE-F-BSA最高分别达到68758.74Da和67740.39Da(均为MSF条件),与BSA相比各增长了1765.68Da、747.33Da。对比之下不难发现,在相同反应条件下,AGE-G-BSA体系的平均分子量大于AGE-F-BSA体系,并且MSF条件下体系分子量始终大于NaN3条件。MALDI-TOF/TOF measures the molecular weight of the sample through the main peak in the spectrum of a single system point. The increase in molecular weight is significantly related to the extension of the main peak, indicating that a series of protein modifications are produced during the non-enzymatic glycosylation reaction. It can be seen from Figure 4 , the molecular weight of BSA used in the experiment was 66993.06Da. In the blank group, with the increase of reaction time, the molecular weight of the system gradually increased. Both under MSF conditions), compared with BSA, they increased by 1765.68Da and 747.33Da respectively. In contrast, it is not difficult to find that under the same reaction conditions, the average molecular weight of the AGE-G-BSA system is greater than that of the AGE-F-BSA system, and the molecular weight of the system under the MSF condition is always greater than that under the NaN 3 condition.

(2) BHFs对AGEs蛋白分子量的作用(2) The effect of BHFs on the molecular weight of AGEs protein

平均分子量结果见表1。加入浓度为0.20mg/mL的裂解剂裂解后体系分子量相较于对照组明显增加,与空白组相比最高增大了209.06Da,约合4个羧基,在裂解后的24个体系中,分子量增幅超过45Da的样品约占总数的60%以上。结果表明,在NaN3条件下,AG裂解后的体外非酶糖基化体系分子量大于BHFs组,而这一结果在MSF条件下却截然相反。并且在AGE-G-BSA体系中,在NaN3条件下裂解剂分子量增加程度大于MSF条件,尤其是在反应时间为3个月的体系中,在NaN3条件下加入AG和BHFs裂解后体系的分子量分别为67804.41Da和67740.41Da,与空白组相比分别增长了209.06Da和145.06Da,而这一增幅在MSF条件下仅为25.98Da和39.62Da,即在NaN3条件下的增幅分别为MSF条件下的8.04和3.66倍。换言之,AGE-G-BSA体系MSF条件下的空白分子量虽大于NaN3条件,但其加入裂解剂后,分子量的增加程度反而较小。而这一结论在AGE-G-BSA体系中并不成立。The average molecular weight results are shown in Table 1. After adding 0.20mg/mL cracking agent, the molecular weight of the system increased significantly compared with the control group, and compared with the blank group, the maximum increase was 209.06Da, which was about 4 carboxyl groups. Among the 24 cracked systems, the molecular weight The samples with an increase of more than 45Da accounted for more than 60% of the total. The results showed that under the NaN 3 condition, the molecular weight of the in vitro non-enzymatic glycosylation system after AG cleavage was larger than that of the BHFs group, but this result was completely opposite under the MSF condition. And in the AGE-G-BSA system, the degree of increase in the molecular weight of the cleavage agent under the NaN 3 condition is greater than that under the MSF condition, especially in the system with a reaction time of 3 months, the addition of AG and BHFs under the NaN 3 condition. The molecular weights are 67804.41Da and 67740.41Da respectively, which are respectively increased by 209.06Da and 145.06Da compared with the blank group, and this increase is only 25.98Da and 39.62Da under the MSF condition, that is, the increase under the NaN3 condition is MSF 8.04 and 3.66 times under the condition. In other words, although the blank molecular weight of the AGE-G-BSA system under MSF conditions was greater than that under NaN 3 conditions, the increase in molecular weight was relatively small after adding the cleavage agent. But this conclusion does not hold in the AGE-G-BSA system.

表1 BHFs裂解前后AGEs蛋白平均分子量Table 1 Average molecular weight of AGEs protein before and after BHFs cleavage

注:图中数据均用平均值±标准偏差的形式表示(n=3),同一指标不同小写字母表示数据间存在显著性差异(p< 0.05 Note: The data in the figure are expressed in the form of mean ± standard deviation (n=3), and different lowercase letters in the same index indicate significant differences among the data ( p<0.05 ) .

3. BHFs对AGEs还原糖含量的作用3. Effect of BHFs on reducing sugar content of AGEs

分别使用Nobio葡萄糖测定试剂盒(葡萄糖氧化酶-过氧化物酶法)及Sigma FrutoseAssay Kit对体系裂解前后体系中的葡萄糖、果糖含量进行测定。The contents of glucose and fructose in the system before and after lysis were measured using Nobio glucose assay kit (glucose oxidase-peroxidase method) and Sigma Frutose Assay Kit respectively.

(1)BHFs对AGE-G-BSA体系AGEs葡萄糖含量的作用(1) Effect of BHFs on AGEs glucose content in AGE-G-BSA system

BHFs对AGE-G-BSA体系中葡萄糖含量的作用如图5所示,在反应时间为1个月的空白组体系中,NaN3和MSF条件下葡萄糖含量分别为0.76±0.02mg/mL和0.55±0.01mg/mL,仅为反应初始浓度(30.00mg/mL)的0.10%,表明美拉德反应在1个月时,其葡萄糖的利用已经基本达到饱和状态,在随后反应时间为3、6个月的体系中,葡萄糖含量无显著变化(p>0.05),并且在MSF条件下,体系葡萄糖含量低于NaN3条件。在NaN3条件下,BHFs和AG对体系葡萄糖含量的作用均不显著(p>0.05),而在MSF条件的体系中,对于反应时间为3、6个月的体系,BHFs裂解后葡萄糖含量显著升高(p<0.05),分别为0.62mg/mL±0.01和0.75±0.01mg/mL,达到空白组的1.48倍和1.80倍。The effect of BHFs on the glucose content in the AGE-G-BSA system is shown in Figure 5. In the blank system with a reaction time of 1 month, the glucose content was 0.76±0.02 mg/mL and 0.55 mg/mL under NaN 3 and MSF conditions, respectively. ±0.01mg/mL, which is only 0.10% of the initial reaction concentration (30.00mg/mL), indicating that the utilization of glucose in the Maillard reaction has basically reached saturation in one month, and the subsequent reaction time is 3, 6 In the system of 1 month, the glucose content had no significant change ( p>0.05 ), and under the MSF condition, the glucose content of the system was lower than that under the NaN 3 condition. Under the NaN 3 condition, neither BHFs nor AG had a significant effect on the glucose content of the system ( p>0.05 ), while in the MSF condition system, for the systems with a reaction time of 3 and 6 months, the glucose content after cleavage of BHFs was significant Increased ( p<0.05 ), respectively 0.62mg/mL±0.01 and 0.75±0.01mg/mL, reaching 1.48 times and 1.80 times of the blank group.

(2) BHFs对AGE-F-BSA体系AGEs果糖含量的作用(2) Effect of BHFs on AGEs fructose content in AGE-F-BSA system

由图6可知,AGE-F-BSA体系中果糖含量与AGE-G-BSA体系中葡萄糖含量变化趋势基本一致,在反应时间为1个月的体系中,果糖含量在NaN3和MSF条件下均为初始浓度0.02%;但与葡萄糖含量变化趋势不同的是,在NaN3条件下,当反应进行到第6个月时,体系中果糖含量显著下降至0.44±0.02mg/mL(p<0.05),仅为反应时间为3个月的体系的69.84%,而这一结果在MSF条件下并不显著(p>0.05)。而与AGE-G-BSA体系中葡萄糖含量变化相似是,在AGE-F-BSA体系MSF条件下的果糖含量也低于NaN3组。果糖含量与葡萄糖含量变化的区别之处还在于,AG在NaN3和MSF条件下对反应时间为3个月的体系均表现出显著的作用(p< 0.05),果糖含量显著升高至1个月的体系的1.21倍和1.14倍(p<0.05),然而BHFs在NaN3条件反应时间为3个月的体系中却显著降低了果糖含量(p<0.05),仅为0.38±0.01mg/mL,而在反应时间为6个月的体系中,随着BHFs和AG的加入,果糖含量均显著升高(p<0.05),尤其在NaN3条件下的体系中,BHFs裂解后的果糖含量为空白组的1.80倍(p<0.05)。It can be seen from Figure 6 that the fructose content in the AGE-F-BSA system is basically the same as the glucose content in the AGE- G -BSA system. The initial concentration was 0.02%; but different from the change trend of glucose content, under the condition of NaN 3 , when the reaction reached the sixth month, the fructose content in the system dropped significantly to 0.44±0.02mg/mL ( p<0.05 ) , only 69.84% of the system with a reaction time of 3 months, and this result was not significant under MSF conditions ( p>0.05 ). Similar to the change of glucose content in the AGE-G-BSA system, the fructose content in the AGE-F-BSA system under MSF conditions was also lower than that of the NaN 3 group. The difference between the fructose content and the glucose content is that AG has a significant effect on the reaction time of 3 months under the conditions of NaN 3 and MSF ( p< 0.05 ), and the fructose content is significantly increased to 1 1.21 times and 1.14 times ( p<0.05 ), however, BHFs significantly reduced the fructose content ( p<0.05 ) in the NaN 3 condition reaction time of 3 months, only 0.38±0.01mg/mL , while in the system with a reaction time of 6 months, with the addition of BHFs and AG, the fructose content increased significantly ( p<0.05 ), especially in the system under the condition of NaN 3 , the fructose content after the cracking of BHFs was 1.80 times of blank group ( p<0.05 ).

4. BHFs对AGEs游离氨基含量的作用4. The effect of BHFs on the content of free amino groups in AGEs

采用OPA法测定体系中游离氨基的含量。取4.0mLOPA试剂于试管中,加入200μL体系,对照组加入相同体积的蒸馏水,混合均匀后,在35℃水浴条件下反应2min,随后利用酶标仪测定体系在340nm处的吸光值A340,以赖氨酸代替样品采用相同方法制作标准曲线,为y=-0.1211x+3.5487(R2=0.998,OD值在0.18-0.90范围),根据曲线计算自由氨基的含量。以赖氨酸浓度(X)(0.18~0.90mg /mL)为横坐标,在340nm处吸光值A340(Y) 为纵坐标绘制标准曲线,线性回归方程为y=-0.1211x+3.5487,R2=0.998,游离氨基含量以百分数计。The content of free amino groups in the system was determined by OPA method. Take 4.0mL of LOPA reagent in a test tube, add 200μL of the system, add the same volume of distilled water to the control group, mix well, and react in a water bath at 35°C for 2min, then use a microplate reader to measure the absorbance A 340 of the system at 340nm. Lysine was used instead of samples to make a standard curve using the same method, which was y=-0.1211x+3.5487 (R 2 =0.998, OD value in the range of 0.18-0.90), and the content of free amino groups was calculated according to the curve. Draw the standard curve with the lysine concentration (X) (0.18~0.90mg/mL) as the abscissa and the absorbance value A 340 (Y) at 340nm as the ordinate, and the linear regression equation is y=-0.1211x+3.5487, R 2 =0.998, the content of free amino groups is expressed as a percentage.

(1) BHFs对AGE-G-BSA体系AGEs游离氨基含量的作用(1) Effect of BHFs on AGEs free amino group content in AGE-G-BSA system

BSA分子结构中的游离氨基是荧光性AGEs生成所必须的活性基团,因而游离氨基含量的变化常被用来表示蛋白质与糖接枝反应的程度。图7表明,在AGE-G-BSA体系中,随着非酶糖基化反应时间的增长,BSA经还原糖糖基化后游离氨基含量显著减少(p<0.05),当反应进行到第6个月时,体系在NaN3和MSF条件下游离氨基含量分别为10.28±0.01%和6.32±0.39%。MSF条件的体系中游离氨基酸含量显著低于NaN3条件(p<0.05)。The free amino group in the molecular structure of BSA is an active group necessary for the generation of fluorescent AGEs, so the change of the free amino group content is often used to indicate the degree of grafting reaction between protein and sugar. Figure 7 shows that in the AGE-G-BSA system, with the increase of non-enzymatic glycosylation reaction time, the content of free amino groups after BSA was glycosylated with reducing sugars was significantly reduced ( p<0.05 ), when the reaction reached the 6th At one month, the content of free amino groups in the system under NaN 3 and MSF conditions were 10.28±0.01% and 6.32±0.39%, respectively. The content of free amino acid in the system under MSF condition was significantly lower than that under NaN 3 condition ( p<0.05 ).

BHFs和AG裂解后体系中游离氨基含量显著升高(p<0.05),二者裂解作用相当(p< 0.05),并且二者对各体系裂解作用间无显著差异(p>0.05),BHFs裂解后MSF条件反应6个月的体系中游离氨基含量达到最高,为11.56±0.04%,而相同条件下AG裂解后的游离氨基含量为11.46±0.05%,分别为空白组的1.82倍和1.83倍。而这一结果在NaN3条件相同反应时间的体系中分别为11.55±0.01%和11.50±0.03%。After the cracking of BHFs and AG, the content of free amino groups in the system increased significantly ( p<0.05 ), and the cracking effects of the two were equivalent ( p< 0.05 ), and there was no significant difference between the cracking effects of the two on each system ( p>0.05 ). The content of free amino groups in the system reacted under MSF conditions for 6 months reached the highest, which was 11.56±0.04%, while the content of free amino groups after AG cleavage under the same conditions was 11.46±0.05%, which were 1.82 times and 1.83 times that of the blank group, respectively. However, this result was 11.55±0.01% and 11.50±0.03% in the NaN 3 condition with the same reaction time.

(2)BHFs对AGE-F-BSA体系AGEs游离氨基含量的作用(2) Effect of BHFs on AGEs free amino group content in AGE-F-BSA system

由图8可知,AGE-F-BSA体系空白组中游离氨基含量的变化与AGE-G-BSA体系有所不同,AGE-F-BSA体系在反应时间为1、3、6个月的体系中无显著变化(p>0.05),在9.76%~11.41%范围内波动,这一结果在相同条件下高于AGE-G-BSA体系中游离氨基含量。而与AGE-G-BSA体系相似的是,加入裂解剂后AGE-F-BSA体系中游离氨基含量升高,在NaN3条件体系中,BHFs和AG虽然对反应时间为1、3个月的体系无显著作用,然而却使反应时间为6个月的体系中游离氨基含量显著升高(p<0.05),且二者作用相当,分别为11.65±0.02%和11.63±0.02%。在MSF条件体系中,AG对于反应时间为1个月的体系裂解作用显著强于BHFs(p< 0.05),在反应时间为3、6个月的体系中,BHFs和AG裂解后体系中游离氨基含量显著升高,并且二者裂解作用相当(p<0.05)。It can be seen from Figure 8 that the change of the free amino group content in the AGE-F-BSA system blank group is different from that in the AGE-G-BSA system, and the AGE-F-BSA system is different in the reaction time of 1, 3, and 6 months. No significant change ( p>0.05 ), fluctuating in the range of 9.76%~11.41%, this result is higher than the free amino group content in AGE-G-BSA system under the same conditions. Similar to the AGE-G-BSA system, the content of free amino groups in the AGE-F-BSA system increased after adding the cracking agent. In the NaN 3 conditional system, although BHFs and AG were sensitive to the reaction time of 1 and 3 months The system had no significant effect, but the content of free amino groups in the system with a reaction time of 6 months was significantly increased ( p<0.05 ), and the effects of the two systems were equivalent, 11.65±0.02% and 11.63±0.02%, respectively. In the MSF condition system, the cracking effect of AG on the system with a reaction time of 1 month was significantly stronger than that of BHFs ( p< 0.05 ). The content was significantly increased, and the cracking effect of the two was equivalent ( p<0.05 ).

Claims (5)

1.荞麦壳黄酮提取物在制备糖基化终末产物裂解剂方面的应用。1. Application of buckwheat husk flavonoid extract in the preparation of glycosylation end product splitting agent. 2.根据权利要求1所述的应用,其特征在于:所述的荞麦壳黄酮提取物,是由下述方法制备的:2. The application according to claim 1, characterized in that: the buckwheat husk flavone extract is prepared by the following method: 1)将荞麦壳粉碎、过60-80目筛,按料液质量比1:5-20加入水,高压加热;1) Crush the buckwheat husk, pass through a 60-80 mesh sieve, add water according to the mass ratio of material to liquid 1:5-20, and heat under high pressure; 2)过滤,在55-65℃下真空浓缩,冷冻干燥20-30h,即获得荞麦壳黄酮提取物。2) Filtration, vacuum concentration at 55-65°C, and freeze-drying for 20-30 hours to obtain buckwheat husk flavone extract. 3.根据权利要求2所述的应用,其特征在于:步骤1)中所述的高压加热为121℃下加热15-25min。3. The application according to claim 2, characterized in that: the high-pressure heating described in step 1) is heating at 121° C. for 15-25 minutes. 4.根据权利要求2所述的应用,其特征在于:步骤1)中所述的高压加热为采用超高压处理装置,压力100-400MPa、保持压力1-5min,高压稳定处理。4. The application according to claim 2, characterized in that: the high-pressure heating described in step 1) adopts an ultra-high pressure processing device, the pressure is 100-400MPa, the pressure is maintained for 1-5min, and the high-pressure stable treatment is performed. 5.根据权利要求4所述的应用,其特征在于:步骤1)中所述的压力为300MPa,保持压力时间2min。5. The application according to claim 4, characterized in that the pressure in step 1) is 300 MPa, and the pressure is maintained for 2 minutes.
CN201710879511.9A 2017-09-26 2017-09-26 Advanced glycation end products decomposition agent Pending CN107898829A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710879511.9A CN107898829A (en) 2017-09-26 2017-09-26 Advanced glycation end products decomposition agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710879511.9A CN107898829A (en) 2017-09-26 2017-09-26 Advanced glycation end products decomposition agent

Publications (1)

Publication Number Publication Date
CN107898829A true CN107898829A (en) 2018-04-13

Family

ID=61840251

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710879511.9A Pending CN107898829A (en) 2017-09-26 2017-09-26 Advanced glycation end products decomposition agent

Country Status (1)

Country Link
CN (1) CN107898829A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030028234A (en) * 2001-09-27 2003-04-08 이형주 Extracts of buckwheat and/or buchwheat chaff with anti-inflammatory effects and composition comprising of the same
CN1634953A (en) * 2003-12-26 2005-07-06 山西省风陵渡开发区众力投资发展有限公司 Medicament for treating diabetes, diabetes complication, its preparation and novel use
CN103431389A (en) * 2013-08-27 2013-12-11 陕西科技大学 A method for continuously extracting buckwheat flavonoids and dietary fiber from buckwheat husk
CN104825552A (en) * 2015-05-15 2015-08-12 吉林农业大学 Buckwheat shell flavonoid extract and application thereof as AGEs (advanced glycosylation endproducts) inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030028234A (en) * 2001-09-27 2003-04-08 이형주 Extracts of buckwheat and/or buchwheat chaff with anti-inflammatory effects and composition comprising of the same
CN1634953A (en) * 2003-12-26 2005-07-06 山西省风陵渡开发区众力投资发展有限公司 Medicament for treating diabetes, diabetes complication, its preparation and novel use
CN103431389A (en) * 2013-08-27 2013-12-11 陕西科技大学 A method for continuously extracting buckwheat flavonoids and dietary fiber from buckwheat husk
CN104825552A (en) * 2015-05-15 2015-08-12 吉林农业大学 Buckwheat shell flavonoid extract and application thereof as AGEs (advanced glycosylation endproducts) inhibitor

Similar Documents

Publication Publication Date Title
CN101678061B (en) Extracts of aster koraiensis, and pharmaceutical composition and functional food comprising the same
Jang et al. Preparation of cellulose microfibril (CMF) from Gelidium amansii and feasibility of CMF as a cosmetic ingredient
US9827275B2 (en) Immunostimulatory compositions and methods of use thereof
CN103229962A (en) Method for improving bioavailability of iron and zinc elements of broad beans
WO2021078296A1 (en) Polysaccharide-peptide complex for lowering blood sugar, blood lipid and glycosylated hemoglobin levels, and preparation method
Munir et al. The antioxidant effect of curcumin on cochlear fibroblasts in rat models of diabetes mellitus
CN108935912B (en) A kind of fish meat protein peptide with DPP-IV inhibition and anti-fatigue functions and preparation method thereof
CN108813090B (en) Preparation method of poultry plasma protein
CN104825552A (en) Buckwheat shell flavonoid extract and application thereof as AGEs (advanced glycosylation endproducts) inhibitor
JP2020000257A (en) Serine racemase activator and skin barrier function enhancer
Liu et al. Stability of antioxidant peptides from duck meat after post-mortem ageing
KR20170033622A (en) Method of lowing collagen molecular weight of pig leather, Hide Splits, fishskin and pig leather produced by the same
JP2018007612A (en) Dietary fiber having protein saccharification inhibiting function and method for producing the same
Horiuchi et al. Advanced glycation end products of the Maillard reaction and their relation to aging
TWI698247B (en) Uses of camellia sinensis callus extract in protecting skin
CN107898829A (en) Advanced glycation end products decomposition agent
Imai et al. Inhibitory Effects of Parachlorella Beijerinckii Extracts on the Formation of Advanced Glycation End Products and Glycative Stress‐Induced Inflammation in an in Vitro Skin Dermis‐Like Model
CN101884766A (en) Healthcare product or medicine for preventing diabetes complication and senium and preparation method thereof
CN111004305B (en) Agaricus blazei small peptide and its preparation method and application
CN108893512B (en) Bee pupa protein peptide with DPP-IV inhibition and anti-fatigue functions and preparation method thereof
Liu et al. Analysis of differentially expressed advanced glycation end product-modified proteins in diabetic rat kidney
TWI862056B (en) Use of antler collagen extract in anti-oxidation and anti-inflammation
CN120616152B (en) Albumin peptide composition capable of promoting immune cell proliferation and preparation method and application thereof
TWI892640B (en) Chenopodium formosanum heptapeptide, preparation method and use thereof
Anfuso et al. Protective Role of Cynara cardunculus L. var. altilis Against Oxidative Stress and Corneal Dysfunction in High Glucose-Damaged Human Corneal Epithelial Cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180413

WD01 Invention patent application deemed withdrawn after publication